Next Wave: Breakthrough Wave 1

Funding is available to purchase a die attach/bonding system capable of performing a wide range of bonding processes, including ultrasonic, flip-chip, and UV curing, which is suitable for prototyping and light production runs. As a result, a crucial aspect for any die attach system under is the ability to be used for bonding runs as small as a single die should this be required. This stipulation lends itself to a semi-automated (i.e. motorised) system, ideally with the capacity to store process recipes to maximise reproducibility should the system be used for light production runs.

Society’s most important advances have stemmed from those willing to think differently about what might be possible. ARIA is an R&D funding agency built to unlock scientific and technological breakthroughs that benefit everyone. Created by an Act of Parliament, and sponsored by the Department for Science, Innovation, and Technology, ARIA funds breakthrough R&D in under explored areas to catalyse new paths to prosperity for the UK and the world.

Provision of Local Accelerator Delivery Services for the Innovation and Technology Fund (ITF), Low Carbon Development Initiative (LCDI) Phase 2 Oxford Policy Management Limited (OPML), with support from the Foreign, Commonwealth and Development Office (FCDO) and Kementerian PPN/BAPPENAS, invites potential suppliers to submit a proposal to act as the local Accelerator Delivery Partner for the ITF Accelerator Programme, providing a locally-based Acceleration Manager and associated technical assistance to grantees funded under the ITF. The overall objective of this assignment is to strengthen the commercial, operational and institutional readiness of ITF grantees through tailored, high-quality technical assistance, delivered fairly and consistently across a diverse cohort. The assignment covers all eight ITF grantees selected under Batch 1 and Batch 2 and includes delivery of a shared in-country bootcamp, individual needs assessments and site visits, and tailored one-to-one accelerator support through to March 2027. It is the responsibility of the tenderer to ensure that proposals are received by 22nd July at 23:00 Indonesia Western Time. Proposals received after this time will not be considered. Any questions or requests for clarification and the Technical and financial proposals should be sent by email to a5043procurement@opml.co.uk within the timescales set out in Section 14. The financial proposals should be send in a separate email in excel file with password protected.

Funding is available to purchase a laser-based photonic component testing system which is capable of rapidly modifying the wavelength (>100 nm/s sweep rate) with a high level of precision (sub-picometer wavelength resolution). Such a system must also be able to accurately measure the wavelength-dependent power to allow for characterisation of a device under test (DUT). Such a system would strongly complement the photonics capabilities available to the QTIC/BIZ community.

Apply for Arts and Humanities Research Council (AHRC) standard research grant funding to support well-defined collaborative projects across the arts and humanities, in areas covered by our remit. You must be based at a UK research organisation eligible for AHRC funding. There is no limit on the value of the grant, the value specified within the summary page is an example.

Apply for funding to work with overseas researchers in the Unites States (US). Submit a collaborative research grant application within the remit of AHRC and US National Science Foundation, Social, Behavioural and Economic Sciences Directorate (NSF-SBE). You must be based at a UK research organisation eligible for AHRC funding. There is no limit on the value of the grant, the value specified within the summary page is an example.

The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Required mechanism focusing on alcohol treatment and recovery research. This NOFO will focus broadly on topics relevant for treatment of and recovery from alcohol use disorder (AUD), including: medications development, precision medicine, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for AUD treatment and recovery.

The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Optional mechanism focusing on alcohol health services. This NOFO will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations.

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research. With this NOFO, the NCI intends to encourage submission of projects devoted to demonstrating that mammalian models or their derivatives used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patients' benefit. These practical goals contrast with the goals of many mechanistic, NCI-supported R01 projects that employ mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors, applicants in response to this FOA could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally

Apply for funding to run a high throughput screen (HTS) using AstraZeneca’s compound library and screening robots. There are two funding opportunities per year that are open to all targets.